Gynecologic Cancer News

In this video, Ronny Drapkin, MD, discusses identifying patients at heightened risk for ovarian cancer.

In this video, Ronny Drapkin, MD, discusses known risk factors for ovarian cancer.

In this video, Ronny Drapkin, MD, discusses how PARP inhibitors changed the field of ovarian cancer treatment.

In this video, Ronny Drapkin, MD, discusses recent advancements in ovarian cancer.

In this video, Ronny Drapkin, MD, discusses challenges in diagnosing ovarian cancer.

The FDA approved a new liquid formulation of thiotepa for the treatment of with adenocarcinoma of the breast or ovary, according to the agent’s manufacturer.

CHICAGO — Individuals with advanced cancer who received a two-component medical cannabis oil reported improvement in cancer-related pain, results from a randomized study showed.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

Robert A. Winn, MD, FAACR, first called for celebration.

The FDA approved the use of durvalumab in combination with carboplatin and paclitaxel followed by single-agent durvalumab for women with mismatch repair-deficient primary advanced or recurrent endometrial cancer.